Grenis-Oflo

Grenis-Oflo is an oral, prescription‑only medication that contains the fluoroquinolone antibiotic ofloxacin. It is marketed in the European Union and is formulated for systemic antibacterial therapy. Ofloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, which blocks DNA replication and transcription. The product is supplied without a specified strength in the available information.

Grenis-Oflo is indicated for the treatment of several bacterial infections where ofloxacin is appropriate.

- Urinary tract infections caused by susceptible organisms - Respiratory tract infections such as acute sinusitis or bronchitis - Skin and soft‑tissue infections including cellulitis and wound infections - Gastrointestinal infections like travel‑related diarrhoea - Other infections caused by bacteria proven to be sensitive to ofloxacin

Side effects reported with ofloxacin may vary in frequency and severity.

Common: - Nausea or vomiting - Diarrhoea or abdominal discomfort - Headache or dizziness - Rash or mild skin reactions - Photosensitivity - Transient elevation of liver enzymes

Serious: - Tendon rupture or tendonitis, especially in the Achilles tendon - Peripheral neuropathy presenting as tingling or numbness - Severe allergic reactions such as anaphylaxis - Cardiac QT interval prolongation that may lead to arrhythmia

Before prescribing Grenis-Oflo, clinicians should consider several precautionary factors to minimize risk.

- History of tendon disorders or recent corticosteroid use - Known QT prolongation, arrhythmias, or electrolyte disturbances - Renal impairment requiring dose adjustment - Unknown safety in pregnancy and lactation; use only if benefits outweigh risks - Documented hypersensitivity to fluoroquinolones or related compounds - Potential for Clostridioides difficile‑associated colitis with broad‑spectrum antibiotics - Use with caution in patients with myasthenia gravis as it may exacerbate muscle weakness

Grenis-Oflo can interact with other medicines, affecting its efficacy or safety.

Avoid: - Antacids or supplements containing magnesium, aluminum, calcium, or iron, which reduce absorption - Warfarin, because of increased anticoagulant effect and INR elevation - Cyclosporine, due to increased cyclosporine plasma concentrations - Theophylline, as ofloxacin may raise theophylline levels and toxicity risk - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that can increase central nervous system side effects

Use with caution: - Corticosteroids, because combined use may raise tendon‑rupture risk - Diabetic agents, as fluoroquinolones can affect blood glucose control